BRAF and melanoma: Compound 110 was found to be the most promising inhibitor against the WM3629 melanoma cell line with IC50 value of 38.6 nM, which also showed enzymatic activities against wild-type BRAF and BRAF (V599E) kinase with IC50 values of 9.45 and 7.82 μM, respectively.